Manipulating RNA sequences using CRISPR-Cas13

CRISPR-Cas13 is an RNA editing technique that can alter protein sequences without modifying the genome in a cell. Recent advances in CRISPR-Cas13 technology mean that it can now be used to locate and even reduce cancer associated gene expression.

Credit: Andrii Vodolazhskyi/

Deoxyribonucleic acid (DNA) contains all the genetic information of an cell. When a protein needs to be synthesized, relevant genes are transcribed into ribonucleic acid (RNA), which is further processed and transported out of the nucleus. Translation of RNA forms a specific sequence of nucleic acids which leads to production of a specific protein.

Manipulation of nucleic acid sequences can serve as a promising and valuable treatment option for a range of genetic diseases. By altering the disease associated sequences to code for functional protein product, diseases could be treated or even cured.

One of the methods used to alter nucleic acid sequence is  clustered regularly interspaced short palindromic repeats (CRISPR)-Cas technology, which can be precisely programmed to alter nucleic acids. These “molecular scissors” not only provide potential cures for genetic diseases, but also provide further insights into single gene diseases, such as cystic fibrosis.

What is CRISPR?

The CRISPR family originates from a bacterium, where it acts as an immune response to viral threats. Palindromic sequences are found to be interspaced between regions of viral DNA from previous bacteriophage infections. CRISPR associated system (Cas) genes are also located nearby, coding for endonucleases and helicases.

Attacking bacteriophage inject their DNA into the cytoplasm and take over the cell to replicate. With the CRISPR-Cas system, viral DNA is cut into fragments which are stored at a CRISPR locus. These loci can be transcribed and resulting RNAs can be used to detect future bacteriophage DNA, thereby acting as an acquired immune response.

CRISPR-Cas system technology

The CRISPR Cas system was adapted by scientists to edit nucleic acid sequences for  research purpose and treatment of genetic disease. RNA is designed to guide cas endonucleases to cut at specific points and edit the nucleic acid sequences.

The traditional CRISPR-Cas system is the Cas-9 system, first identified in Streptococcus Thermophilus. Once cas-9 is introduced into the cells, special designed guide RNA is used to direct the Cas9 endonuclease to cut the DNA in a highly specific manner. Once  fragmented, the cell can repair the broken DNA using DNA repair mechanisms including non-homologous end joining (NHEJ) and homology directed repair (HDR).This leads to alterations  in the sequence of DNA. This alteration further leads to permanent changes in nucleic acid sequence and can be used to cure genetic conditions. However, permanently changing the genome possess several risks and unknown side effects.


Recent advances have led to the development of CRISPR-Cas13 system, which knocks down messenger RNA. Since RNA codes for the sequence of nucleic acids produced, editing the sequence of RNA can therefore temporarily edit gene expression without the serious risks associated with permanent changes to the genome.

This could be used in the treatment of acute diseases and temporary reduction in inflammation during organ transplantation. In addition to the possible therapeutic roles, the CRISPR-cas13 system can also provide insights into RNA processing in disease, for example RNA editing and alternative splicing.

Since the changes to gene levels are only transient, this allows scientists to investigate the possible gene knock outs which could cure disease. The RNA levels can be returned to normal once the CRISPR-cas13 system is removed from the cell.. Due to this the changes would not be passed onto the offsprings. Some diseases are also caused due to abnormally high levels of RNA from a specific gene. Therefore, this system could be used to treat these diseases without permanently effecting the genome which could lead to disastrous side effects.

A recent study by Zhang et al has shown that one member of the cas 13 family, CRISPR-Cas13a, can be used to reduce cancer-assocaited gene expression. The researchers also managed to design a fluorescently tagged version of this endonuclease that does not cleave the target RNA, but instead binds and allows localization analysis.

Future prospects for CRISPR-Cas13

One of the major future challenges for the use of CRISPR-cas13 technology as a treatment option is suitable method of delivery into human tissues. Additionally, major ethical issues involved in editing the DNA, including worries over genome editing and genetic enhancement in embryos. However, this technology could enable a new and revolutionary approach for both treating and curing genetic diseases.

Further Reading

Last Updated: Jul 19, 2023

Hannah Simmons

Written by

Hannah Simmons

Hannah is a medical and life sciences writer with a Master of Science (M.Sc.) degree from Lancaster University, UK. Before becoming a writer, Hannah's research focussed on the discovery of biomarkers for Alzheimer's and Parkinson's disease. She also worked to further elucidate the biological pathways involved in these diseases. Outside of her work, Hannah enjoys swimming, taking her dog for a walk and travelling the world.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Simmons, Hannah. (2023, July 19). Manipulating RNA sequences using CRISPR-Cas13. News-Medical. Retrieved on July 13, 2024 from

  • MLA

    Simmons, Hannah. "Manipulating RNA sequences using CRISPR-Cas13". News-Medical. 13 July 2024. <>.

  • Chicago

    Simmons, Hannah. "Manipulating RNA sequences using CRISPR-Cas13". News-Medical. (accessed July 13, 2024).

  • Harvard

    Simmons, Hannah. 2023. Manipulating RNA sequences using CRISPR-Cas13. News-Medical, viewed 13 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration